PRM Pharma

Executive Summary

PRM Pharma is a private specialty pharmaceutical company leveraging the FDA's 505(b)(2) regulatory pathway to develop lower-dose formulations of established prescription medicines for rare and metabolic diseases. Founded in 2017 and headquartered in San Diego, the company aims to optimize dosing to improve patient outcomes and reduce side effects, addressing unmet needs in niche therapeutic areas. By repurposing known drugs with improved pharmacokinetic profiles, PRM Pharma reduces development risk and accelerates time-to-market compared to novel drug development. The company's focus on rare diseases allows for targeted commercial strategies and potential for orphan drug exclusivity. Despite limited public information, PRM Pharma's business model aligns with successful precedents in the 505(b)(2) space, offering efficient path to approval and market access.

Upcoming Catalysts (preview)

• Q3 2026IND or Pre-IND Meeting for Lead Candidate70% success
• Q1 2027Publication of Preclinical Data in Peer-Reviewed Journal60% success
• 2027Strategic Partnership or Licensing Deal40% success